Is billion to one public?
Yes, BillionToOne operates as a publicly traded enterprise. The molecular diagnostics and precision medicine company successfully completed its initial public offering on the NASDAQ Global Select Market, trading under the ticker symbol BLLN. Prior to transitioning into the public markets, the enterprise completed multiple venture capital funding rounds backed by prominent institutional investors to scale its proprietary Quantitative Counting Technology platform. As a public corporation, it files regular financial disclosures and quarterly earnings reports with the Securities and Exchange Commission, allowing public market retail and institutional investors to buy and sell its shares openly.
Related FAQs
American Express Membership Rewards points possess a flexible valuation that varies significantly depending on how you choose to redeem them, meaning their cash value is not a fixed amount.
Bitdeer Technologies Group commands a corporate market capitalization of approximately $2.81 billion USD.
BillionToOne is widely regarded as an innovative, fast-growing molecular diagnostics and precision health company specializing in advanced prenatal screening and oncology liquid biopsy testing.
BillionToOne has evolved past its early-stage startup origins into a publicly traded commercial-stage molecular diagnostics enterprise.
Yes, clinical tests offered by BillionToOne—such as its UNITY prenatal screen and Northstar oncology liquid biopsy panels—are widely covered by Medicare, Medicaid, and major private commercial health insurance providers.
Yes, BillionToOne, Inc. is a publicly traded enterprise.